Aldeyra Therapeutics Reports Top-Line Results From The Phase 2 Clinical Trial Of Orally Administered ADX‑629
Portfolio Pulse from Benzinga Newsdesk
Aldeyra Therapeutics reported positive top-line results from the Phase 2 clinical trial of orally administered ADX-629, showing a significant reduction in cough frequency compared to placebo. A Phase 2 trial for ADX-629 in moderate alcohol-associated hepatitis is expected to begin in H2 2023.
June 27, 2023 | 11:07 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Aldeyra Therapeutics' positive top-line results from the Phase 2 clinical trial of ADX-629 may boost investor confidence and potentially impact the stock price positively in the short term.
The positive top-line results from the Phase 2 clinical trial of ADX-629 indicate that the drug is effective in reducing cough frequency. This news may increase investor confidence in the company's pipeline and potentially lead to a positive impact on the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100